Introduction
In recent years, various de novo methods have been developed for designing drug delivery systems (DDSs). 1, 2 An ideal DDS should convey a suitable concentration of drug to targeting sites and enhance the drug efficacy. 3, 4 Thus, one of the main challenges to reach this aim is finding a suitable delivery carrier. 5, 6 Currently, among various carriers including polymeric particles, 7, 8 nanomaterials, 6 microspheres, 9 dendrimers 10 and liposomes 11 which were used as potential drug carriers, nanomaterial demonstrate advantages for drug delivery. 12 The efficiency of conventional drugs and facilitate many of the free drug therapeutic pitfalls can be enhanced by nanoparticle-based therapeutics. Nanocarriers can improve considerably the effect and delivery of drugs, especially when drugs are poorly water-soluble. Nanoparticle-drug conjugates under different stages were developed in clinical therapies and illustrates the clinical success of nanoparticle therapies. 4, 13 dimethylformamide (DMF), CHCl 3 and all other materials were purchased from Merck.
Characterization and analysis UV-Vis absorption spectra were obtained on a Shimadzu 1700 Model UV-Vis spectrophotometer. The Fourier transform infrared (FTIR) spectra were recorded on an FT-IR spectrometer (Bruker Instruments, model Aquinox 55, Germany) in the 4000-400 cm −1 range at a resolution of 0.5 cm −1 as KBr pellets. X-ray diffraction (XRD) measurements were performed at room temperature by Siemens diffractometer with using Cu-Kα radiation at 35 kV in the scan range of 2θ from 5 to 25°. The surface morphology and EDX of the samples were investigated using a scanning electron microscope (SEM) (LEO 1430VP) after coating the samples with gold films. The dynamic light scattering (DLS) and zeta potential measurements were obtained with a DLS-ZP/Particle Sizer (Microtrac, model Nanotrac Wave).
Synthesis of CMC/MOF-5/GO bio-nanocomposite
According to the modified Hummers method, GO was prepared from graphite powder. 42 A flask emblematic 46 mL of H 2 SO 4 (98%) was immersed into an ice bath. Then 2.0 g graphite was added to the flask and stirred vigorously. Next, 6.0 g KMnO 4 was slowly added into the flask and for about 30 minutes the reaction temperature was kept below 20°C in an ice bath. The flask containing the reaction mixture was then heated with a water bath at a temperature of 35°C, and until a thick paste was formed the reaction mixture was stirred for about 45 minutes. 46 mL water was added to the flask and the reaction temperature was increased to 90°C then the reaction mixture was stirred for about 30 minutes. Finally, 280 mL water was added to the mixture, followed by a slow addition of 10 mL of 30% aq. H 2 O 2 . A yellow dispersion was obtained and until about pH 7 the mixture was washed severally with deionized water to remove the remained salt, then the product was dried under vacuum (50°C) for about 24 hours.
The GO (0.33 g) was dispersed in DMF solution by sonication to get DMF emulsion of GO. The CMC/ MOF-5/GO bio-nanocomposite was prepared via the solvothermal route with some modifications on MOF-5.
14, 43 In a typical reaction, zinc nitrate hexahydrate (5.2 g), BDC (1.0 g), and CMC (0.33 g) were mixed in 35 mL of GO/DMF solution. The mixture was treated solvothermal at 120°C for 25 hours. Finally, the resulted solid sample was washed with DMF and CHCl 3 , and CMC/MOF-5/GO was obtained by vacuum drying at 80°C using desiccator equipped with a heater. In order to the synthesis of pure MOF-5, the same procedure was applied without the employment of CMC and GO.
Drug loading and release studies
In purpose of drug loading in the GO and CMC/MOF-5/GO, equal mass (200 mg) from each sample was of small molecules such as drug molecule under ambient conditions. 22 Moreover, the critical drawbacks of MOFs and GO may resolve by the composition of GO and MOFs. 23 Recently, some new results about MOF-GO hybrids 24 have reported using various MOFs, for example, Zn-based MOF (MOF-5), 22 Cu-based MOF (HKUST-1 or Cu 3 (BTC) 2 , BTC = 1,3,5-benzene tricarboxylate), 25 Zrbased MOF (UiO-66) 26 and Fe-based MOF (MIL-100). 27 However, as far as we know, there are still few studies on the potential of the MOF-GO composites in the drug delivery systems, so evaluation of this system has a good novelty for controlling the drug release. Typically, many of nanoparticles, for instance, MOF-GO composites suffer from low solubility in the physiological conditions; therefore, these materials need to be modified for the improvement of solubility. Carboxymethylcellulose (CMC) is an anionic water-soluble biopolymer that is one of the cellulose derivatives. [28] [29] [30] CMC have unique characteristics such as pH-sensitivity, hydrophilicity, nontoxicity, biodegradability, and biocompatibility. [31] [32] [33] In biomedical applications because of these CMC features, considerable interests have been focused on CMC prepared carriers. 8, 34, 35 Therefore, for modification of the nanoparticle, CMC can be a good candidate. 36 Tetracycline (TC) is an industrially available antibiotic used to treat a number of infections. This includes acne, cholera, brucellosis, plague, malaria, and syphilis. 37 One of the major side effects which were observed after oral administration of TC is irritation of the gastrointestinal tract (GIT). To decrease the high GIT side effects, which caused by the oral use of TC , the drug can be encapsulated into biocompatible support as enteric coated dosage forms. As well as, nanomaterial supports with the high surface area such as GO could enhance the medicinal efficiency, and also the medical performance can be improved even more through modification of nanoparticle.
In our ongoing research program, related to developing the new drug delivery system 38,39 based on our previous investigations on GO, 40, 41 the CMC-modified MOF-5/ GO bio-nanocomposite was prepared as a novel drug delivery system. Antibacterial drug TC was highly loaded to the CMC/MOF-5/GO, then the release behavior was investigated. Drug loading and release manner of prepared CMC/MOF-5/GO by combining the complementary features of the three materials (CMC, MOF-5 and GO) was well optimized. The obtained results showed that this desired carrier system could be potentially used in the antibacterial oral delivery systems.
Experimental
Material CMC with the degree of substitution (DS) 0.55-1.0 and viscosity 15000 MP/s (1% in H 2 O, 25°C) were obtained from Nippon Paper Chemicals Co., Ltd., Japan. TC was purchased from Sigma-Aldrich. Zinc nitrate hexahydrate, 1,4-benzenedicarboxylate (BDC), N,N-immersed in 20 mL aqueous solution of 100 ppm drug concentration. After a continuous shaking for 72 hours in the dark, the TC loading capacity was determined using UV-Vis spectrophotometer at 276 nm. The TC-loaded GO (TC@GO) and TC-loaded CMC/MOF-5/GO (TC@ CMC/MOF-5/GO) were collected by centrifuging and washed thoroughly to remove unloaded drug then dried at 40°C in the oven.
To study the release of TC, in a typical experiment, 10 mg of TC@GO and TC@CMC/MOF-5/GO were immersed in 10 mL buffered solution. For this propose, during a specific period of time, the carrier was suspended in the mediums with pH 1.2, pH 6.8 and pH 7.4 which respectively mimicked the pH of the simulated gastric fluid, the first zone of intestinal fluid and the second zone of intestinal fluid. Firstly, they were immersed to pH 1.2 (for 2 hours), then to pH 6.8 (for 2 hours), and subsequently to pH 7.4 (for 4 hours). At the certain time intervals, adequate amounts of samples were taken up and in order to maintain the volume of buffer constant, the same amount of fresh buffered was replaced.
The loading capacity and cumulative release data were obtained by using a predetermined calibration curve for TC drug. The amount of loaded and released drug respectively was calculated with the following 2 formulas (Eq. 1 and Eq. 2): According to the previous report using various kinetics models (Table 1 ) the release kinetics analysis data were analyzed. 44, 45 Antibacterial Studies Against Escherichia coli bacteria (gram negative) and Staphylococcus aureus bacteria (gram positive), the antibacterial properties of the prepared materials were tested. From an overnight culture, grown aerobically in Mueller-Hinton (MH) broth at 37°C, the inoculum of E. coli and S. aureus were prepared. By measuring optical density at 600 nm (OD600) the bacterial concentration was determined. Based on the broth microdilution methods the bacterial minimum inhibitory concentration (MIC) for blank and TC-loaded GO and CMC/MOF-5/ GO were determined. 46 The lowest concentration of an antibacterial material that will inhibit the visible growth of a microorganism after overnight incubation is defined MIC. 47 To determine MIC, from overnight cultures, the bacterial suspensions were prepared and adjusted to 10 6 CFU/mL. Then a 100 µL of fresh MH broth, 40 µL of bacterial suspension and 60 µL of various concentrations of TC (1, 2, 25, 50, 100, 150, 200 µg/mL), blank and TCloaded GO and CMC/MOF-5/GO (50, 100, 150, 250, 500, 1000, 1500, 2000 µg/mL) were added to 96-well plate. Table 1 460
The kinetics models used to fit the release data. To assess the viability of the tested organisms, a positive growth control of basal medium was contained. Under linear shaking, the microplates were incubated aerobically at 37°C for 24 hours. Finally, by detecting the well's conformation the lowest concentration inhibiting the bacterial growth (the MIC value) was measured. Fig. 1 demonstrates FT-IR spectra to characterize CMC, MOF-5, GO and CMC/MOF-5/GO. The symmetric stretching and asymmetric stretching of the carboxylate groups in MOF-5 and CMC were respectively observed at 1508, 1725 cm -1 and 1539, 1401 cm 
Results

FT-IR analysis
XRD analysis XRD patterns of the GO, MOF-5, and CMC/MOF-5/GO
were shown in Fig. 2 . The significant increase of layer spacing with a high degree of orientation of GO was evidenced by border peak at 2θ 11.16° which obvious in the GO XRD spectrum. 48 The XRD pattern of MOF-5 is in good consistency to previous reports (Fig. 2) . 43 The broad reflection at 2θ value of about 20° in the CMC/MOF-5/ GO XRD pattern is related to the amorphous nature of CMC. Furthermore, the XRD pattern of CMC/MOF-5/ GO is similar to the MOF-5, which demonstrates that the MOF-5 structure is preserved. The XRD results proved that the crystalline structure of the MOF-5 component did not distort by the composition of MOF-5, GO and CMC in the CMC/MOF-5/GO bio-nanocomposite. 43 
EDX analysis
Element information of samples was obtained using EDX analysis (Fig. 3) . The spectrum of CMC (Fig. 3A) shows signals for the presence of C, O and Na with weight percentages 62.23, 36.68 and 0.89 W%, respectively. The EDX signals for MOF-5 (Fig. 3B) 
Zeta potential
The zeta potential results of GO and CMC/MOF-5/GO were provided to confirm the drug delivery ability of materials (Fig. 4A) . The zeta potential of GO is about −16.1 mV because of -COO -groups on the GO. Due to the existence of Zn 2+ in MOF-5, the zeta potential of CMC/MOF-5/GO is about +4 mV that is +20.1 mV much higher than GO. 
Solubility analysis
Colloidal stability of the GO and CMC/MOF-5/GO was studied in 0.9 wt% NaCl solutions. However, in distilled water GO was well dispersed but in the physiological environment, it was easy to aggregate. As seen in Fig. 4B , in 0.9 wt% NaCl solutions, the GO (0.2 mg/mL) after a few hours was precipitated, while the CMC/MOF-5/GO (0.2 mg/mL) was still well dispersed for more than 20 days. Therefore, the solubility of CMC and MOF-5 modified GO was improved. This behavior of bio-nanocomposite effectively can be relative to the high solubility nature of CMC.
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Size distribution analysis
The size of GO and CMC/MOF-5/GO were performed in aqueous solution by using DLS measurement. It was found that the average size of GO was 121.5 d.nm (Fig. 4C) . However, after the modification of GO with CMC and MOF-5, an average size of CMC/MOF-5/GO 344 d.nm was obtained under the same instrumental conditions (Fig. 4C) . Fig. 5 shows the SEM images of the GO and CMC/MOF-5/GO. In Fig. 5a can be seen the agglomeration of stacked graphene sheets due to the strong specific interactions and dispersive forces between the surface groups on the graphene-like layers. 50 In contrast, the CMC/MOF-5/GO consists of a spongy structure with square and lamellar shapes on the graphene sheets, which was derived from the morphology of CMC and MOF-5 respectively (Fig. 5B) .
Morphological analysis
Drug loading and release
Pure TC drug was loaded in the GO and CMC/MOF-5/ GO then the drug loading of carrier respectively was calculated 2.59 and 6.85 wt% using UV-Vis spectroscopy (Fig. 6) . Since the loading of the drug was performed in the distilled water, the TC molecule is a zwitterion. In this condition, the surface of the CMC/MOF-5/GO in comparison with GO is partially positive charge that is seen in Zeta potential data. 51 Hence, it seems there is an attractive force between TC molecules and surface of the CMC/MOF-5/GO. This was supported by TC loading data which showed an increase in the TC loading capacity of the CMC/MOF-5/GO in comparison with GO. For elucidating the potential of the synthesized carrier as an oral DDS, drug release experiment was carried out in simulated conditions with in-vivo process. The Fig. 5b shows the release profiles of the TC-loaded GO and CMC/ MOF-5/GO over 8 hours at 37 o C. By comparing the charts, the amount of drug release is enhanced for CMC/MOF-5/GO than GO which might be due to the combination of CMC, MOF-5 and GO as the bio-nanocomposite structure. In the GO 0.12 mg, the drug was released at 8 hours while for CMC/MOF-5/GO the amount of drug release was 0.65 at 8 h. To reveal the drug release kinetics, the release data were fit using several models (Table 2) , as described previously. 44 The release data were best fitted with Hixson-Crowell and, to some extent, with three seconds root of mass models (Table 1) .
Antibacterial activity tests
To assess the applicability of prepared bio-nanocomposite as an antibacterial agent, we tested them at different concentrations against S. aureus and E. coli. The microdilution method was employed to determine their MIC to evaluate their antibacterial activity. The evaluation included various concentrations of blank and TC-loaded GO and CMC/MOF-5/GO, in order to analyze and to compare the enhanced antibacterial behavior associated with modified bio-nanocomposite. Table 2 shows the MIC values of samples to inhibit both bacterial strains. The obtained data showed that the blank GO is not any antibacterial activity against S. aureus and E. coli while the TC@GO show that antibacterial activity against S. aureus with the MIC of 500 µg/mL. Antibacterial activity against S. aureus with the MIC of 1000 µg/mL was shown for blank CMC/MOF-5/GO. However, for TC@CMC/MOF-5/GO, MIC of 500 and 1000 µg/mL are required to inhibit the growth of S. aureus and E. coli bacteria, respectively.
Discussion
Recently, much attention has been paid to developing new methods for designing new DDSs with the controlled drug release potentials. 52 In traditional drug delivery system, the drug dosage in the tissue increases rapidly and then drops. 53 Plasma level of each drug is described by overhead and under levels as toxic and ineffective, respectively. 54 An ideal drug delivery system should convey a suitable concentration of drug to targeting sites while other tissues will be kept safe. 3, 55 Thus, one of the main challenges is finding a suitable delivery carrier to reach this goal. In this work, we have successfully composed GO with biopolymer CMC and MOF-5 in goals of enhanced solubility, antibacterial activity, delivery and controlled release of the drug into specific location. Drug loading and releasing experiments showed that the TC was efficiently loaded on and released from the CMC/ MOF-5/GO bio-nanocomposite.
The FT-IR results could be good evidences for the interactions between the -COOH of GO, CMC, and BDC with Zn ++ of CMC/MOF-5/GO. The XRD results prove that the GO component in the CMC/MOF-5/GO cannot induce a distortion in the crystalline structure of MOF-5 component. 43 The obvious change in size distribution indicated that the CMC and MOF-5 acted as a cross-linking agent to prepare the spongy structure of GO and the size diameter of CMC/MOF-5/GO particles was increased after the modification process. In order to clarify the effect of CMC and MOF-5 on the spongy structure of GO, the morphological analysis shows that some polymers may fill in the structure to support the framework, and some may react with the functional groups on the GO.
TC is an industrially available antibiotic used to treat a number of infections. This includes acne, cholera, brucellosis, plague, malaria and syphilis. 37 One of the major side effects which were observed after oral administration of TC is irritation of the gastrointestinal tract (GIT). To decrease the high GIT side effects caused by severity of upon TC oral organization, the drug can be encapsulated into biocompatible support as enteric coated dosage forms. As well as, nanomaterial supports with high surface area such as GO could enhance the medicinal efficiency, and also the medical performance can be improved even more through modification of nanoparticle. 56 For this propose, during a specific period of time, carrier was suspended in the mediums with pH 1.2, pH 6.8 and pH 7.4 which respectively mimicked the pH of the simulated gastric fluid, the first zone of intestinal fluid and the second zone of intestinal fluid. Due to the high loading of the drug, the positive-charged and spongy structure of CMC/ MOF-5/GO nanocarrier the TC release was enhanced and showed antibacterial activity to negatively charged E. coli bacteria compared with TC@GO. It is clear that there is a significant improvement in TC release and a strong antibacterial activity by modification with MOF-5 and CMC in comparison with bare GO.
Conclusion
In present work, we have successfully composed GO with biopolymer CMC and MOF-5 in aims of enhanced solubility, antibacterial activity, delivery and controlled release of drug into the specific location. Drug loading and releasing experiments showed that the TC was efficiently loaded on and released from the CMC/MOF-5/GO bionanocomposite. Antibacterial activity tests showed that the TC@CMC/MOF-5/GO has an antibacterial activity to negatively charge E. coli bacteria compared with TC@ GO. These properties are related to the water-soluble and positively charge features of CMC/MOF-5/GO which was created by modification of GO with CMC and MOF-5. According to the results, the TC-loaded CMC/MOF-5/ GO can be considered as potential candidates for targeted delivery and controlled release of oral delivery.
What is the current knowledge? √ Carboxymethylcellulose/MOF-5/GO bio-nanocomposite (CMC/MOF-5/GO) successfully synthesized using the solvothermal technique. √ Tetracycline (TC) was encapsulated in the GO and CMC/ MOF-5/GO. √ The drug release profiles showed that the TC-loaded CMC/ MOF-5/GO has an effective protection functionality against stomach pH.
What is new here? √ With controlling the TC release in the gastrointestinal tract conditions, the long-time stability of drug dosing was enhanced. √ The collected data showed that the TC-loaded CMC/MOF-5/GO has the antibacterial activity to negatively charge E. coli bacteria in contrast to TC-loaded GO.
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